Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present consensus among 11 TipRanks analysts is for a reasonable Buy rating of shares in CVS Health, with an average price target of eighty four dolars.

The analysts priced targets range from a high of $101 to a low of sixty one dolars.

From its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management solutions. The retail or Long Term Care segment has selling of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products and associated services, which includes medical, pharmacy, dental, behavioural health, healthcare relief capabilities. The Corporate segment involves in providing management as well as administrative services. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *